Synergistic effects in the designs of neuraminidase ligands: Analysis from docking and molecular dynamics studies

被引:24
作者
Yang, Zhiwei [1 ]
Nie, Yingkun [2 ]
Yang, Gang [1 ]
Zu, Yuangang [1 ]
Fu, Yujie [1 ]
Zhou, Lijun [1 ]
机构
[1] NE Forestry Univ, Minist Educ, Key Lab Forest Plant Ecol, Harbin 150040, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 2, Dept Rheumatol, Harbin 150086, Peoples R China
关键词
Neuraminidase ligands; Fragment approach; Synergistic effects; H-bonds; Rational drug designs; INFLUENZA-VIRUS NEURAMINIDASE; DRUG DESIGN; INHIBITORS; FRAGMENT; OSELTAMIVIR; BINDING; RECOGNITION; DISCOVERY; POTENT; SIMULATION;
D O I
10.1016/j.jtbi.2010.08.029
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Docking and molecular dynamics were used to study the nine ligands (see Scheme 1) at the neuraminidase (NA) active sites. Their binding modes are structurally and energetically different, with details given in the text. Compared with 1A (oseltamivir carboxylate), the changes of core template on and functional groups in the other ligands cause the reductions of interaction energies and numbers of H-bonds with the NA proteins. Nonetheless, all these ligands occupy the proximity space at the NA active sites and share some commonness in their binding modes. The fragment approach was then used to analyze and understand the binding specificities of the nine ligands. The contributions of each core template and functional group were evaluated. It was found that the core templates rather than functional groups play a larger role during the binding processes; in addition, the binding qualities are determined by the synergistic effects of the core templates and functional groups. Among the nine ligands, 1A (oseltamivir carboxylate) has the largest synergistic energy and its functional groups fit perfectly with the NA active site, consistent with the largest interaction energy, numerous H-bonds with the NA active-site residues as well as experimentally lowest IC50 value. Owing to the poorer metabolizability than oseltamivir, large contribution of the benzene core template and fine synergistic effects of the functional groups, the 4-(N-acetylamino)-5-guanidino-3-(3-pentyloxy)benzoic acid should be an ideal lead compound for optimizing NA drugs. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:363 / 374
页数:12
相关论文
共 68 条
[1]  
*ACC INC, 2005, IN VERS
[2]   GENERALIZED LANGEVIN EQUATION APPROACH FOR ATOM-SOLID-SURFACE SCATTERING - GENERAL FORMULATION FOR CLASSICAL SCATTERING OFF HARMONIC SOLIDS [J].
ADELMAN, SA ;
DOLL, JD .
JOURNAL OF CHEMICAL PHYSICS, 1976, 64 (06) :2375-2388
[3]   THE NEURAMINIDASE OF INFLUENZA-VIRUS [J].
AIR, GM ;
LAVER, WG .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1989, 6 (04) :341-356
[4]   Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations [J].
Amaro, Rommie E. ;
Cheng, Xiaolin ;
Ivanov, Ivaylo ;
Xu, Dong ;
McCammon, J. Andrew .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (13) :4702-4709
[5]  
[Anonymous], AFF US GUID
[6]   On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9 [J].
Aruksakunwong, Ornjira ;
Malaisree, Maturos ;
Decha, Panita ;
Sompornpisut, Pornthep ;
Parasuk, Vudhichai ;
Pianwanit, Somsak ;
Hannongbua, Supot .
BIOPHYSICAL JOURNAL, 2007, 92 (03) :798-807
[7]   Hydrophobic benzoic acids as inhibitors of influenza neuraminidase [J].
Atigadda, VR ;
Brouillette, WJ ;
Duarte, F ;
Babu, YS ;
Bantia, S ;
Chand, P ;
Chu, NM ;
Montgomery, JA ;
Walsh, DA ;
Sudbeck, E ;
Finley, J ;
Air, GM ;
Luo, M ;
Laver, GW .
BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (11) :2487-2497
[8]   BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design [J].
Babu, YS ;
Chand, P ;
Bantia, S ;
Kotian, P ;
Dehghani, A ;
El-Kattan, Y ;
Lin, TH ;
Hutchison, TL ;
Elliott, AJ ;
Parker, CD ;
Ananth, SL ;
Horn, LL ;
Laver, GW ;
Montgomery, JA .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (19) :3482-3486
[9]  
BECCATI D, 2009, INVESTIGATIONS PREBI
[10]   Current and future antiviral therapy of severe seasonal and avian influenza [J].
Beigel, John ;
Bray, Mike .
ANTIVIRAL RESEARCH, 2008, 78 (01) :91-102